Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. Int J Chron Obstruct Pulmon Dis. 2020; 15:3193-3199.

View in: PubMed

subject areas

alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency
Forced Expiratory Volume
Humans
National Heart, Lung, and Blood Institute (U.S.)
Pulmonary Disease, Chronic Obstructive
Registries
Retrospective Studies
United States

authors with profiles

Viswanathan Ramakrishnan
Tatsiana Y Beiko